Company intelligence / Profile preview

Phytopharm plc

Godmanchester, Cambridgeshire, UKphytopharm.tilda.ws ↗

Ownership: Private
Development stage: Phase 2

Overview

As of the last public reports, Phytopharm had two main clinical-stage products—Cogane™ and Myogane™—both orally active neurotrophic factor modulators. Cogane™ was in development as a potential disease-modifying agent for Parkinson’s, Alzheimer’s, and Huntington’s diseases. Myogane™ targeted ALS and other orphan neurodegenerative conditions. Additional preclinical programs included candidates for asthma/COPD and vascular dementia. The company was publicly listed but has since ceased operations; its website and trading are no longer active.

Therapeutic areas: PulmonologyNeurology
Modalities: Small molecules (neurotrophic factors)
Industry: Biotech

Drug pipeline

8 assets

smilagenin

7 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Phytopharm plc.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phytopharm plc.

Explore the full profile